External Funding Opportunities
NIH Tobacco, Alcohol, and Cannabis Policy Research for Health Equity
The purpose of this PAR is to support policy research projects that examine new or adapted policies pertaining to tobacco, alcohol, and/or cannabis in the U.S., with a particular focus on how the policy or policies influence tobacco, alcohol, and cannabis use or secondhand exposure among populations experiencing disparities. Funded projects will involve authentic engagement with one or more community organizations with the aim of promoting equity in cancer prevention by addressing tobacco, alcohol, and cannabis use and exposure. The long-term goal is to support tobacco, alcohol, and cannabis policy research studies that will improve health equity and promote cancer prevention.
R01 Deadline: Februrary 5 | R21 Deadline: February 16
NIH-NCI Mentored Research Scientist Development Award to Promote Diversity (K01)This Funding Opportunity Announcement (FOA) is a continuation of the NCI Mentored Research Scientist Development Award to Promote Diversity (K01) to enhance the diversity of thought in the NCI-funded cancer research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor. This FOA is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial.
Deadline: Februrary 12
NIH-NCI Research Opportunities in Established Cancer Epidemiology Cohort Studies (U01)
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages grant applications to support research in established cancer epidemiology cohort studies, defined as studies that have achieved their initial planned recruitment goal. Applications must include hypothesis-based research using data from an established cohort study and are expected to include support for cohort maintenance, continued follow-up, and sharing of the existing resources in addition to addressing research questions across the cancer control continuum.
Deadline: Februrary 28
NIH Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01)
Through this NOFO, the National Cancer Institute (NCI) seeks research project grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.
Deadline: Februrary 5
NIH Molecular Imaging of Inflammation in Cancer (R01)
Through this NOFO, the National Cancer Institute (NCI) invites research grant applications for the development and application of current and emerging molecular imaging methods to gain fundamental insights into cancer inflammation in vivo. This NOFO encourages applications focused on developing integrated imaging approaches to investigate the role of inflammation in cancer through strong cross-discipline collaboration between cancer basic science researchers and imaging scientists. These collaborations are expected to advance the science and understanding of cancer inflammation interactions.
Deadline: Februrary 5
NIH NCI Clinical and Translational Exploratory/Developmental Studies (R21)
Through this NOFO, the National Cancer Institute (NCI) intends to support preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, comparative oncology, symptom management, or reduction of cancer disparities. This includes (but is not limited to) development and testing of the following: new molecular agents or biologics for cancer treatment; management strategies for cancer-related symptoms or treatment-related toxicity; cancer screening or diagnostic tools, such as imaging techniques; cancer preventive agents or approaches; predictive and prognostic biomarkers for patient selection or stratification; clinically relevant in vivo or in vitro tumor models (including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines); and strategies to address therapeutic outcome disparities among underserved populations. In addition to novel agents, new treatment strategies may involve repurposed agents or novel combinations of interventions (including radiation), based on established mechanisms of action.
Deadline: Februrary 13
NIH Notice of Special Interest (NOSI): Increasing Uptake of Evidence-Based Screening in Diverse Populations Across the Lifespan This NOSI encourages highly innovative translational research focused on the delivery of multilevel interventions to improve uptake of evidence-based screening services that promote health equity and that are recommended by expert committees (e.g., the USPSTF, CPSTF, AAP, ACOG). Multilevel interventions are one tool to reduce health disparities and promote health equity because they address the dynamic interplay of multiple levels of socioecological influence, including those at the individual, interpersonal, family, organizational, neighborhood, community, and societal levels.
Deadline: Varies by Institute
Young Investigator Grants
Foundation: Alex’s Lemonade Stand Foundation for Childhood Cancer
Website: http://www.alexslemonade.org/grants/guidelines
Amount: Up to $180,000
Overview: The Young Investigator grant is a three-year award designed to support early career researchers, such as postdoctoral fellows, clinical fellows, or instructors, pursuing promising childhood cancer research ideas. These grants aim to cultivate the best and brightest researchers of the future who demonstrate a commitment to a research career in pediatric cancer. A mentor is required, and a career development plan must be included.
Eligibility:
- Applicant institutions must be based in the United States or Canada. Applicants need not be United States citizens. Funds must be granted to nonprofit institutions or organizations.
- Applicants must have an MD, PhD, or MD/PhD or equivalent and must not have achieved an appointment higher than Instructor. Assistant Professors, including adjuncts at this level, will not be considered. In addition:
- Applicants from accredited clinical fellowship programs are automatically eligible for the duration of their training and during their first three years at the Instructor level.
- Applicants not from accredited clinical fellowship programs must meet the following criteria:
- Applicants holding an MD or MD/PhD must be within seven years from the granting of the last doctoral degree at the time of application.
- Applicants holding a PhD must be within four years from the granting of the last doctoral degree at the time of application.
- A minimum of 75% of the applicant’s time during the Young Investigator period must be allocated as non-clinical protected time for all research activities. This percentage of time includes both Young Investigator activities and the applicant’s other research responsibilities.
- Research mentor(s) must be identified and have a track record in pediatric cancer research. If no such record exists, a co-mentor with such a record must be identified. The application must document the mentor(s) involvement in experimental design and execution. A detailed plan for training activities is required.
DIPG Research Game Changer Grant
Foundation: ChadTough Defeat DIPG Foundation
Website: https://www.chadtough.org/research/grant-application/
Deadline: Application due February 3, 2025
Amount: Up to $600,000
Overview: The ChadTough Defeat DIPG Game Changer Grant provides three years of funding for hypothesisdriven research projects. The proposed research must represent an innovative approach to a major challenge in DIPG/DMG research. The funded projects must have the potential to lead to groundbreaking discoveries in the field and transform our understanding of the tumorigenesis process or our ability to treat or detect DIPG.
Eligibility:
- Applicant must hold an M.D. and/or Ph.D. by the application deadline.
- Applicant must be employed by an academic institution, nonprofit research institution, or laboratory.
- Applicant does not need to be a U.S. citizen.
DIPG Research New Investigator Grant
Foundation: ChadTough Defeat DIPG Foundation
Website: https://www.chadtough.org/research/grant-application/
Deadline: Application due February 3, 2025
Amount: Up to $400,000
Overview: The ChadTough Defeat DIPG New Investigator Grant provides three years of funding to a new DIPG/DMG investigator for hypothesis-driven research projects. The investigator may be either a newly independent researcher establishing a new DIPG/DMG research lab, or an established researcher who has not previously conducted brain tumor research.
Eligibility:
- Applicants must have an academic appointment and be in their first independent faculty position or equivalent at an accredited college, university, medical school, or other research facility.
- Applicants should be in their faculty role for not more than 6 years at the time of application.
- Independence is typically demonstrated by a full-time faculty appointment, a tenure-track position, allocated space, a start-up package, and institutional commitment. We understand that this definition may not align to the practices of all institutions.
- Applicants who are beyond their first independent faculty position for more than 6 years are eligible if they have no previous research on brain tumors.
- Applicants must be employed by an academic institution, nonprofit research institution, or laboratory.
- Applicants do not need to be U.S. citizens.
New Investigator Research Grant Program
Foundation: Leukemia Research Foundation, Inc.
Website: https://leukemiarf.org/research/guidelines/
Deadline: LOI due February 14, 2025
Amount: Up to $150,000
Overview: Our New Investigator Research Grant Program supports early-career investigators of exceptional creativity who propose highly innovative research projects with the potential to impact broad, essential areas of leukemia research. For the program to support the best and brightest minds, applications are sought from investigators who reflect the full diversity of the research workforce and represent diverse backgrounds, institutions, and geographic locations.
Eligibility:
- Applicants must be independent investigators affiliated with a non-profit academic institution at the time funding commences and for the duration of the award.
- New investigators are within seven years of their first independent faculty-level position when the grant would be awarded. Years as a resident physician, fellow physician, or post-doctoral fellow are training years and are not included in the seven-year guideline.
- A researcher must be in an independent faculty-level position at the time the application is submitted. An independent position is a scientist who has dedicated laboratory space, directly hires and supervises laboratory personnel, and makes all decisions concerning research activities and use of the grant funds.
- Adjustments for career interruptions can be made. These could include but are not limited to family leave, military service, major illness, or injury. It is the responsibility of the applicant to point out and document such interruptions.
- Applicants are not required to be US citizens. Research projects from outside the US are eligible.
- Applicants with a KO8, R00, or R99 grant are eligible. The total grant amount will not be applied toward the $175K per year threshold on total direct costs.
- DOE, DOD, NSF, R21, or other grants with less than $175K per year in total direct costs are permitted.
- Only one LOI may be submitted from the same applicant (Principal Investigator).
- Research Funding
- Acknowledgement
- External Funding
- Publication Support
- Pilot Grants Program Calendar